| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO, SGS |
| Model Number: | Chlorpheniramine Maleate |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Carton Box or Drum |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/P, D/A, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 144689-63-4 | Mf: | C29H30N6O6 |
|---|---|---|---|
| MW: | 446.5 | Einecs: | 646-413-5 |
| Specification: | 98% | Certificate: | GMP/ISO9001 |
| High Light: | CAS 144689-63-4 Hypoglycemic Drugs,Hypoglycemic Drugs Olmesartan Medoxomil,CAS 144689-63-4 active pharmaceutical intermediates |
||
CAS 144689-63-4 Pharmaceutical Intermediates Hypoglycemic Drugs Olmesartan Medoxomil
|
Product Name: |
Olmesartan Medoxomil |
|
Synonyms: |
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl] 4-yl)methyl)-4-(;OlMesartan MedoxoMil SynoyM:4-(1-Hydroxy-1-Methylethyl)-2-propyl-1-[[2'-(1H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-1H-iMidazole-5-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl ester;OLMESARTAN MEDOXOMIL USP ORGANIC CHEMICA;OMST;1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;Olmesartan medoxomil for system suitability;Olmesartan MedoxomiI;Olmesartan Medoxomi |
|
CAS: |
144689-63-4 |
|
MF: |
C29H30N6O6 |
|
MW: |
558.59 |
|
EINECS: |
604-433-1 |
|
Product Categories: |
Cardiovascular APIs;OMNICEF;Aromatics;Bases & Related Reagents;Inhibitor;API;Active Pharmaceutical Ingredients;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Olmesartan |
The Introductction of Olmesartan Medoxomil
Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion.
Olmesartan Medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan has a dual method of elimination, with about 60% eliminated by the liver and the remainder by the kidney. In situations of impaired renal or hepatic function, the alternative excretion pathway can compensate for the compromised one. Olmesartan is not metabolized by the cytochrome P450 enzyme system and therefore has a low potential for metabolic drug interactions, a feature that may be of importance when treating patients on multiple drug regimens, such as the elderly. Olmesartan is well tolerated and has an excellent safety profile that is comparable to that of placebo. In addition, olmesartan provides 24-h blood pressure control with a once-daily dosing. In head-to-head studies, olmesartan delivered superior blood pressure reduction when compared with other angiotensin-II receptor antagonists at their recommended doses.
The Function&Application of Olmesartan Medoxomil
Olmesartan is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
Olmesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs).
Olmesartan works by relaxing blood vessels so that blood can flow more easily.
The COA of Olmesartan Medoxomil
|
Item |
Specification |
Result |
|
Appearance |
White or almost white crystalline powder |
white crystalline powder |
|
Identification |
|
|
|
Water |
≤0.5% |
0.18% |
|
Residue On Ignition |
≤0.1% |
0.06% |
|
Heavy Metals |
≤0.001% |
<0.001% |
|
Related Compounds |
≤0.5% |
0.2% |
|
Assay |
98.5%~101.5% on the anhydrous and solvent-free basis |
99.5% |
|
Conclusion |
The results conforms with USP standards |
|